Notwithstanding all the challenges clouding its future, the Chinese pharmaceutical industry and market managed to post higher growth again in 2010. The Chinese official sources expect the overall output value of the Chinese pharmaceutical industry to reach CNY 1,256 billion in 2010, up 25% year on year (compared with 21% in 2009) and accounting for no less than 7% of the Chinese GDP. The Chinese drug market size in 2010, on the other hand, is expected to reach CNY 755.6 billion at the retail price level, up 22% year on year (up from 21% growth in 2009).

For many pharmaceutical MNCs, China is now a leading overseas market and it is likely to become their largest foreign market within a decade. Moreover, China has recently become a favorite destination for innovative drug R&D and many big pharma MNCs are increasingly relocating and outsourcing their R&D to the country.

The rising importance of China prompted many leading MNCs to elevate the corporate status of their Chinese subsidiaries in 2010 to ensure reinforced HQ attention. To ensure faster growth, MNCs reversed decisively their past prudence for acquisition of Chinese firms and opened the floodgate of M&As late last year with a flurry of major deals.

Nonetheless, the pharmaceutical industry in China continues to face mounting challenges and the country's ever-changing legal, regulatory and market environments of China's healthcare sector pose the single biggest challenge to foreign companies. Deepening Chinese healthcare reform is reshaping the industry landscape, changing market dynamics and impacting the business models of multinational pharmaceutical companies in the country.

Meanwhile, China's drug regulation regime has continued to evolve in search of better solutions to secure drug safety and efficacy at the same time of containing costs, fostering innovation and supporting industry development.

Following China's WTO entry in 2002, the country has been moving its intellectual property rights regime closer to those found in many more developed nations. Despite the substantial progress made in this area, a number of issues continued to remain. On the other hand, as China's legal system evolves and becomes more mature, the Chinese population has become increasingly aware of their patient rights, leading to a growing number of lawsuits and a more challenging legal environment for pharma companies. 

There are success stories from all categories of players, whether they are foreign or local, large or small, newcomer or established, private or state-owned. However, to be one of the success stories require a thorough understanding of the sector, ability to face and tackle challenges, flexibility to deal with changes, and skills to maneuver through complex situations.

To cater for the growing needs of headquarter pharmaceutical executives for better understanding of the Chinese market, the Seminar was launched in 2009 by AmIntell, the organizer of Pharma CI Conference and Pharma Market Research Conference, and Pharma China, the most influential English media and source of business intelligence covering the Chinese pharmaceutical / biopharmaceutical industry and market.

"Pharma China Seminar - Building Success in China’s Pharma Sector" is a one-day seminar providing insights into contemporary trends/issues and the most important aspects of the Chinese pharmaceutical industry and marketplace today.

On the basis of our successful experience with the event in 2009 and 2010, Pharma China Seminar 2011 will refocus its agenda to provide more in-depth coverage of and strategic insights into four key aspects of Chinese pharma business including 1) latest trends and issues in drug regulation and healthcare policies; 2) impacts of deepening healthcare reform on the pharmaceutical industry, marketplace and business models of MNCs; 3) changing dynamics in pharma marketing & distribution channels; 4) M&A trends and diversification drive of pharma companies; 5) R&D, partnership and licensing trends & strategies; and 6) emerging IP/legal issues.

Eight leading experts of the Chinese pharmaceutical/healthcare sector with different specialization will share their expertise and knowledge through exclusive data, detailed analysis, case studies and interactive panel discussions.

Who should attend?

-  Senior executives

-  Strategic planning/business development/CI/market research executives

-  Executives responsible for outsourcing

-  R&D/licensing/regulatory executives

-  Regional HQ executives

-  Expatriate executives in China

-  CRO executives

-  Investment/VC professionals

Why should you attend?

- Learn about the present state and future outlook of the Chinese pharma industry and marketplace
-  Identify emerging opportunity areas and growth drivers

-  Examine major intellectual property issues and legal risks

-  Stay informed for the latest developments in Chinese drug regulation and healthcare policy

-  Gain insights into key aspects of Chinese pharma business

-  Brainstorm successful China business strategies

What does the seminar cover?

-  Contemporary trends, issues and challenges

-  Future growth drivers, opportunities and outlook

-  Healthcare reform and impacts on pharma sector

-  Intellectual property/patent related issues

-  Pricing and reimbursement/health insurance system

-  Pharmaceutical marketing and distribution channel strategies

-  Regulatory process for new drug development and registration

-  Considerations for developing successful China business strategies

-  Rising global importance of China – sourcing and licensing opportunities

For registration and information, please Contact: Kelly Yueh
Tel: +1 212 228 7974 or +1 713 398 6888 Email: kelly@pharmachinaseminar.com or info@pharmachinaseminar.com